Register by January 24 to save up to $1200
- 00Days
- 00Hrs
- 00Mins
- 00Secs
Anna SenczukSenior Director, mRNA Process Development at CSL SeqirusSpeaker
Profile
At CSL Seqirus, Anna is responsible for sa-mRNA process development with teams in Waltham, MA and Holly Springs, NC. She joined Seqirus in 2022 and led process development to support phase 1 clinical trial manufacturing of H5N1 and H2N3 sa-mRNA vaccines. Her previous accomplishments include development of platforms for multiple modalities: mRNA (GreenLight Bio), bifunctional antibodies (Amgen) and acid-switch antibodies (Shire). While working on antibody downstream process intensification, Anna developed dual-salt HIC process and primary clarification models. She contributed or led the downstream development of several commercialized products (Prolia, Xgeva, Vectibix, Abrysvo).
Agenda Sessions
sa-mRNA's Structure and Manufacturing Process Affect Its Final Structure and Functionality
, 4:15pmView Session